Document is current
Any future updates will be listed below
-
Authors
Cheng, Wenwen
Gaggero, Silvia
Hasan Bou Issa, Lama
Ouelkdite, Aïcha
Escure, Guillaume
Cozzani, Adeline
Njosse Tchantchou, Yanick
Carlier, Noémie
Wauquier, Emilie
Decool, Gauthier
Tilmont, Rémi
Podvin, Benjamin
Leprohon, Malo
Shekarkar, Mojtaba
Fléchon, Léa
Kasprowicz, Angélina
Groux-Degroote, Sophie
Moreaux, Jérôme
Arnulf, Bertrand
Corre, Jill
Villenet, Céline
Martinet, Ludovic
Leleu, Xavier
Figeac, Martin
Facon, Thierry
Jin, Wenfei
Mitra, Suman
Manier, Salomon
-
Funding
Funding for this research was provided by:
Johnson and Johnson
Intergroup Francophone du Myélome
- License Information
-
More Information
Article History
Received: 24 May 2026
Accepted: 21 August 2026
First Online: 5 September 2026
Declarations
Ethical approval: The French National Agency for the Safety of Medicines and Health (ANSM) and the Ethical Committee “Sud-Mediterranee II” (reference 219 A10) approved the protocol (ID# 19.02.28.43641). The IFM2017-03 trial (registered as NCT03993912 on 2019-10-17, ) and the correlative studies were conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. All the patients provided written informed consent. The trial was promoted by Lille University Hospital (CHU Lille) in collaboration with the IFM and with the support of Johnson and Johnson.
Consent to participate: Informed consent was obtained from all participants in this study.
Competing interests: The authors declare no competing interests.
